Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report released on Friday. The firm issued a hold rating on the stock.

Separately, HC Wainwright dropped their price objective on Oncternal Therapeutics from $30.00 to $28.00 and set a buy rating for the company in a research note on Monday, April 15th.

Oncternal Therapeutics Price Performance

NASDAQ ONCT remained flat at $8.75 during mid-day trading on Friday. 337 shares of the company traded hands, compared to its average volume of 6,373. The stock has a market capitalization of $25.89 million, a price-to-earnings ratio of -0.61 and a beta of 1.28. The firm’s fifty day moving average price is $8.79 and its 200 day moving average price is $8.31. Oncternal Therapeutics has a twelve month low of $5.57 and a twelve month high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCT) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($3.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.09) by ($0.02). Oncternal Therapeutics had a negative return on equity of 95.87% and a negative net margin of 5,029.17%. The company had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $0.17 million. During the same period last year, the firm posted ($4.00) earnings per share. On average, analysts predict that Oncternal Therapeutics will post -10.67 earnings per share for the current fiscal year.

Insider Buying and Selling at Oncternal Therapeutics

In related news, Director Robert James Wills bought 3,086 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The shares were purchased at an average cost of $8.96 per share, with a total value of $27,650.56. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at $89,600. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have bought 10,714 shares of company stock worth $92,736. 8.00% of the stock is currently owned by insiders.

Institutional Trading of Oncternal Therapeutics

An institutional investor recently raised its position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC grew its position in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) by 79.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 500,000 shares of the company’s stock after acquiring an additional 221,250 shares during the quarter. Pasadena Private Wealth LLC owned about 16.96% of Oncternal Therapeutics worth $268,000 as of its most recent SEC filing. Institutional investors and hedge funds own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.